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Abstract
Introduction: Women with HER2
+ or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in
part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399
residue, BRCA1 locus alternative product, which while sharing 1365 residues with the full-length product of this tumor
suppressor gene, BRCA1/p220, it has oncoprotein-like properties. Here, we examine whether BRCA1-IRIS is a valuable
treatment target for HER2
+ and/or TN/BL tumors.
Methodology/Principal Findings: Immunohistochemical staining of large cohort of human breast tumor samples using
new monoclonal anti-BRCA1-IRIS antibody, followed by correlation of BRCA1-IRIS expression with that of AKT1, AKT2, p-AKT,
survivin and BRCA1/p220, tumor status and age at diagnosis. Generation of subcutaneous tumors in SCID mice using
human mammary epithelial (HME) cells overexpressing TERT/LT/BRCA1-IRIS, followed by comparing AKT, survivin, and
BRCA1/p220 expression, tumor status and aggressiveness in these tumors to that in tumors developed using TERT/LT/
Ras
V12-overexpressing HME cells. Induction of primary and invasive rat mammary tumors using the carcinogen N-methyl-N-
nitrosourea (NMU), followed by analysis of rat BRCA1-IRIS and ERa mRNA levels in these tumors.
High BRCA1-IRIS expression was detected in the majority of human breast tumors analyzed, which was positively
correlated with that of AKT1-, AKT2-, p-AKT-, survivin, but negatively with BRCA1/p220 expression. BRCA1-IRIS-positivity
induced high-grade, early onset and metastatic HER2
+ or TN/BL tumors. TERT/LT/BRCA1-IRIS overexpressing HME cells
formed invasive subcutaneous tumors that express high AKT1, AKT2, p-AKT and vimentin, but no CK19, p63 or BRCA1/p220.
NMU-induced primary and invasive rat breast cancers expressed high levels of rat BRCA1-IRIS mRNA but low levels of rat ERa
mRNA.
Conclusion/Significance: BRCA1-IRIS overexpression triggers aggressive breast tumor formation, especially in patients with
HER2
+ or TN/BL subtypes. We propose that BRCA1-IRIS inhibition may be pursued as a novel therapeutic option to treat
these aggressive breast tumor subtypes.
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Introduction
Apoptosis evasion increases cancer cells’ chances to encounter
further transforming mutations that can lead to resistance to
therapy and/or disease progression [1,2]. Apoptosis resistant cells
often loose expression of tumor suppressors, such as p53 [3,4],
which is mutated in ,50% of breast cancers, or gain expression of
oncogenes such as AKT, which is overexpressed in ,40% of
breast cancers [5]. Part of AKT ability to induce malignant tumor
progression and chemo-drug resistance lies in its ability to enhance
expression of pro-survival proteins, e.g., survivin [5–8].
HER2 is a tyrosine kinase surface receptor belonging to the
epidermal growth factor receptor family, which includes HER1
(aka, EGFR), HER3 and HER4 [9,10]. The HER2 gene is located
on chromosome 17 and encodes 185 kDa protein [9,11]. EGFR
or HER2 knockout mice show attenuated lobular structures and
milk production, suggesting a role in postnatal development of the
breast [9,12]. HER family members dimerize to form functional
receptors that are stimulated by auto-phosphorylation and then
phosphorylate/activate a wide range of intracellular signaling
cascades [9,13]. Alterations in the HER family members have
been detected in many cancers, including breast cancer [9,14].
HER2 amplification is observed in 15–30% of breast cancer cases
and is often associated with poor prognosis [9,14]. Herceptin (aka,
trastuzumab) is an effective neutralizing monoclonal antibody to
HER2 that blocks it’s signaling and thus function [9,15,16].
Therefore, HER2 amplification is also a predictive factor for
response to systemic therapy [9,17,18].
The triple negative/basal-like (TN/BL) breast cancer subtype
comprises ,15% of all breast cancers and is defined as estrogen
(ERa)-, progesterone (PR)- and HER2- (not amplified) receptor
negativity, but basal-associated markers- (e.g., cytokeratin 5/6 and
17) positivity [19]. TN/BL tumors is associated with a poor
prognosis and while they are responsive to a wide range of
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with a visceral metastases including lung, liver and brain
metastasis. Based on gene expression arrays data, the molecular
features of TN/BL breast cancers often overlap with those of
BRCA1-assocaited tumors.
We recently discovered BRCA1-IRIS, a 1399 residue BRCA1
locus product [20]. Its mRNA contains an uninterrupted open
reading frame that extends from codon 1 of the BRCA1/p220
reading frame in exon 2 to the end of exon 11. It then continues
in-frame for 34 more triplets into intron 11 where it terminates,
hence the name In-frame Reading of BRCA1 Intron 11 Splice
variant (IRIS). Although it and the full-length product of this locus,
the tumor suppressor BRCA1/p220 [21] share 1365 residues,
unlike BRCA1/p220, BRCA1-IRIS possesses oncogenic func-
tions. For example, BRCA1-IRIS overexpression induces over-
replication by inhibiting geminin negative function at DNA
replication origins [20], and over-proliferation by up-regulating
cyclin D1 expression [22,23]. BRCA1-IRIS overexpression also
induces resistance to apoptosis induced by chemo-, geno-, and cell-
toxic stresses in human mammary (HME) and ovarian (HOSE)
epithelial cells by inhibiting p53 and/or enhancing AKT and
survivin expression and activation [24,25]. Thus generating cells
resistant to chemotherapeutic agents, such as etoposide, ionizing
or UV-radiation, and oxidative stresses [24,25].
Together, these data suggest that part of BRCA1-IRIS
oncogenic function lies in its ability to promote formation of
apoptosis resistance and thus aggressive tumor cells. To confirm
that in vivo and to investigate the oncogenic role of BRCA1-IRIS in
details, we used three different approaches. First, we immunohis-
tochemically stained and analyzed a large cohort of primary breast
tumor samples using a newly generated BRCA1-IRIS monoclonal
antibody. We found that BRCA1-IRIS is overexpressed in the
majority of breast tumors analyzed, especially those of the HER2
+
and TN/BL subtypes. BRCA1-IRIS-positive tumors were high-
grade, aggressive and metastatic tumors that expressed higher
levels of AKT and survivin, and lacked expression of BRCA1/
p220 compared to BRCA1-IRIS-negative tumors. Second, we
analyzed subcutaneous xenografts tumors developed by HME cells
overexpressing TERT/SV40 large T-antigen (LT)/BRCA1-IRIS
or /Ras
V12 in SCID mice. We found that TERT/LT/BRCA1-
IRIS-induced (hereafter BRCA1-IRIS-induced) tumors were more
invasive and showed increase expression of AKT and survivin
when compared to TERT/LT/Ras
V12-induced (hereafter Ras
V12-
induced, see [26]) tumors. Third, we analyzed primary as well as
invasive breast tumors generated in rats following exposure to N-
methyl-N-nitrosourea (NMU). We found that carcinogen-induced
rat breast cancers overexpress rat BRCA1-IRIS mRNA in some
aggressive primary tumors or upon disease progression. Collec-
tively, BRCA1-IRIS overexpression appears to promote formation
of aggressive, invasive and/or metastatic breast cancers and
implies that inhibiting BRCA1-IRIS expression and/or activity
could be pursued as a novel therapeutic option to treat breast
cancer patients, especially those with HER2
+ and/or TN/BL
diseases.
Results
Generation of immunohistochemical grade mouse
monoclonal anti-BRCA1-IRIS antibody
To study BRCA1-IRIS expression in vivo, a mouse anti-BRCA1-
IRIS monoclonal antibody that recognizes an epitope in BRCA1-
IRIS intron 11 was developed. The specificity of this antibody was
validated by three separate approaches. 1) Double immunostain-
ing of HME cells transfected with Myc-tagged BRCA1-IRIS
cDNA (for 48 h) with anti-Myc tag antibody (9E10) and this anti-
BRCA1-IRIS antibody. In these cells identical staining pattern
was detected (Figure 1A–D). 2) Transfection of parental or
BRCA1-IRIS overexpressing HME cells (hereafter IRIS) with
luciferase or BRCA1-IRIS specific siRNA (against intron 11 [20])
for 72 h. In these cells, this antibody detected clear difference in
BRCA1-IRIS expression in isogenic cells. Indeed, low endogenous
BRCA1-IRIS level in the HME cells (see also [20,22,23]), while
high BRCA1-IRIS level in the IRIS cells (Figure 1E). Moreover,
BRCA1-IRIS silencing abolished the signal in both cell lines
(Figure 1E). 3) Immunohistochemical staining of invasive breast
cancer samples with pre-absorbed antibody (i.e., pre-incubated
with intron 11 peptide). This treatment led to complete absence of
signal (Figure 1F and arrow in 1G). Thus, we concluded that we
have developed a BRCA1-IRIS specific monoclonal antibody that
can be used in immunohistochemistry on paraffin-embedded
tumor samples. However, a relatively harsh antigen retrieval step
consisting of incubating the sections for 20 minutes at 37uC with
10 mM pepsin is required.
To analyze BRCA1-IRIS expression in breast tumors, two
cohorts of paraffin embedded tissue microarrays (TMA) were
acquired. The first was a test cohort; a commercial TMA (Biomax.
us) that consisted of 66 normal/cancer adjacent tissues, 180 ductal
carcinoma in situ (DCIS), 100 invasive, and 165 metastatic breast
tumor samples. The second was a confirmation cohort, consisting
of disease-free adult tissues (including; kidney, liver, placenta,
spleen and mammary tissues) and 326 breast tumor samples
(different stages) acquired from the Hawaiian Surveillance, Epidemi-
ology and End Results (SEER) collection. Both sets were constructed
in quadruplicate, each containing one sample from a different
region of a tumor at 4 mm.
Following immunohistochemical staining of the test cohort,
BRCA1-IRIS-positive vs. negative cells was counted in at least 10
high power fields of each tumor. The data showed that BRCA1-
IRIS is expressed at very low level in normal breast tissues
(Figure 1H and arrow in 1I), at moderate level in DCIS tumors
(Figure 1J and see BRCA1-positive [solid arrow] vs. -negative
[dashed arrow] in Figure 1K), and at very high level in invasive
(Figure 1L and arrow in 1M) and metastatic tumors (not shown).
Taken together we concluded that BRCA1-IRIS expression
increases in breast cancer as early as DCIS.
In keeping with our earlier observations that showed BRCA1-
IRIS exclusive chromatin association [20], and its function in
replication [22] and transcription [23] (processes known to occur
at the nuclear matrix and in the nucleolus [27–30]). Here too
BRCA1-IRIS staining was predominantly confined to the nuclear
matrix (see arrow in Figure 1M) and the nucleolus (see arrowheads
in Figure 1M).
Immunohistochemical features of BRCA1-IRIS-positive
breast tumors
To confirm the upregulation of BRCA1-IRIS in breast tumors,
the second cohort was stained with the new anti-BRCA1-IRIS
antibody. Disease-free liver (Figure S1A and S1B), placenta
(Figure S1C and S1D), and spleen (Figure S1E and S1F, see also
[20]) tissues all stained positive, whereas disease free kidney and
normal mammary glands (see Figure 1H and I) were negative
(Figure S1G and S1H). These data show that BRCA1-IRIS
expression is also high in highly proliferative tissues.
We recently showed that BRCA1-IRIS overexpression pro-
motes expression of AKT1, AKT2, p-AKT and survivin in human
ovarian normal and cancer cell lines [25]. To evaluate whether
this also occur in breast tumors in vivo, TMA slides from the same
tumor blocks were immunohistochemically stained with BRCA1-
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antibodies. Staining was scored as follows; 0=no staining (,1% of
the cells stained); 1+=weak (1–10% of the cells stained);
2+=medium (10–50% of the cells stained); 3+=strong (.50%
of the cells stained), and staining scores ,10% were considered
negative tumors.
In this conformational cohort as well, the majority, 84%
(n=274) of the tumors were BRCA1-IRIS-positive, while only
16% (n=52) were BRCA1-IRIS-negative. The majority of the
BRCA1-IRIS-positive tumors (Figure 2A and D) stained positive
for AKT1, AKT2, p-AKT and survivin and negative for BRCA1/
p220. Indeed 176 (64%, see example in Figure 2B and 2E), 180
(65%, see example in Figure 2C and 2F), 188 (68%, see example in
Figure 2G and 2J) and 175 (63%, see example in Figure 2H and
2K) of the 274 BRCA1-IRIS-positive tumors stained positive for
AKT1, AKT2, p-AKT and survivin, respectively, whereas only 4
(1%) of the BRCA1-IRIS-positive tumors stained positive for
BRCA1/p220 (Figure 2I and 2L). Note that BRCA1/p220-
negative tumors often show no or little cytoplasmic staining with
BRCA1/p220 antibody [31]. In contrast, 19 (37%), 18 (35%), 15
(29%) and 17 (33%) of the BRCA1-IRIS-negative tumors (n=52)
stained positive for AKT1, AKT2, p-AKT and survivin,
respectively, whereas the majority were BRCA1/p220-positive
(data not shown).
We then examined the associations of expression-levels between
BRCA1-IRIS and AKT1, AKT2, p-AKT, and survivin in
BRCA1-IRIS-positive tumors using State v.11 to calculate Fisher’s
exact p values (Table 1) and Spearman correlation coefficients (r,
Figure 3). According to the Fisher’s exact test, significant
associations between BRCA1-IRIS and AKT1 (p-value=0.012,
Table 1), or AKT2 (p=0.006, Table 1) or p-AKT (p=0.030,
Table 1), but not survivin (p=0.542, Table 1) were observed.
Spearman correlation coefficient test, on the other hand, showed
moderate yet significant correlations between the expression of
BRCA1-IRIS and AKT2 (Spearman rank correlation r=0.16,
p=0.003, Figure 3) or p-AKT (r=0.13, p=0.017, Figure 3) only.
These data suggest that even in breast tumors BRCA1-IRIS
overexpression correlates with high expression/activation of AKT
(especially AKT2) and to a lesser extent survivin.
High expression BRCA1-IRIS in HER2
+ and TN/BL breast
tumors
HER2
+ and TN/BL, as previously stated, are the most
aggressive breast tumor subtypes. HER2
+ tumors often acquire
resistance to Herceptin (the only targeted therapy for these
tumors), and TN/BL while responsive to chemotherapies, thus far,
we have no targeted therapies for these tumors. To test whether
BRCA1-IRIS is a useful chemotherapeutic target for either of
these tumor subtypes, we identified a cohort of HER2
+ (n=32)
and a cohort of TN/BL (n=72) tumors. Stained tumors with
BRCA1-IRIS, AKT (AKT1+AKT2) and survivin were then
analyzed. There was also some information with regards to tumor
grade and tumor stage available.
In the HER2
+ cohort (n=32), 26 tumors (81%) were BRCA1-
IRIS-positive (Table 2), and only 6 tumors (19%) were BRCA1-
IRIS-negative. There was significant strong correlation between
BRCA1-IRIS expression and AKT (r=0.752, p=9 610
26,
Figure 1. Expression of BRCA1-IRIS in breast tumor samples. (A) DAPI stained HME cells transfected with Myc-tagged BRCA1-IRIS cDNA. Same
cell stained with anti-Myc (red, B), anti-BRCA1-IRIS (green, C). (D) Merge of B and C. (E) Expression of BRCA1-IRIS in HME or BRCA1-IRIS overexpressing
cells (IRIS) following transfection of luciferase or BRCA1-IRIS siRNA. (F and G) are low and high magnification images of invasive breast cancer section
stained with pre-absorbed anti-BRCA1-IRIS antibody. Expression of BRCA1-IRIS in paraffin embedded normal mammary epithelial tissue (H and I),
DCIS (J and K) or invasive breast cancer tissues (L and M). H, J and L are low magnification images, whereas I, K and M are high magnification images.
Note the BRCA1-IRIS-psoitive (solid arrow) and -negative (dashed arrow) cells in K. Also note that while all sections are counter stained with
hematoxylin, for technical reasons, the staining was done for shorter time in J, K, L and M compared to F, G, H and I. (N) Expression of 18S and BRCA1-
IRIS mRNA (in duplicates) in 5 normal (N) and 19 breast tumors (T). Bars are, 400 mm in H, J, 200 mm in F, K and L, 100 mm in I and M and 50 mmi nG .
doi:10.1371/journal.pone.0034102.g001
BRCA1-IRIS Promotes Aggressive Breast Cancer
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34102Table 2) or survivin (r=0.859, p=1 610
26, Table 2) expression.
Six HER2
+ tumors were BRCA1-IRIS-negative (19%, Table 2),
and from these, 3 tumors (50%) were AKT-positive (p=0.621,
Table 2) and 5 tumors (83%) were survivin-positive (p=0.822,
Table 2). Further, in the TN/BL cohort (n=72), 63 (88%) were
BRCA1-IRIS-positive (Table 2), while only 9 (12%) were BRCA1-
IRIS-negative. There was significant strong correlation between
BRCA1-IRIS expression and AKT (r=0.748, p=0.00043,
Table 2) or survivin (r=0.834, p=0.0038, Table 2) expression.
Nine TN/BL tumors were BRCA1-IRIS-negative (12%, Table 2),
and from these 7 tumors (78%) were AKT-positive (p=0.492,
Table 2) and 7 tumors (78%) were survivin-positive (p=0.432,
Table 2). Taken together, these data show that BRCA1-IRIS is
overexpressed in two of the most aggressive breast tumor subtypes
and that its overexpression correlates with increased AKT and
survivin in these tumors.
Figure 2. Expression of BRCA1-IRIS, AKT1, AKT2, p-AKT, survivin and BRCA/p220 in breast tumors. Representative sections of TN/BL
breast tumor tissues showing low (A, B, C, G, H, and I) and high (D, E, F, J, K, and L) magnification images of sections stained for BRCA1-IRIS (A and D),
AKT1 (B and E), AKT2 (C and F), p-AKT (D and J), survivin (H and K), and BRCA1/p220 (I and L). Bars are 400 mm in A–D and 200 mm in E–H.
doi:10.1371/journal.pone.0034102.g002
Table 1. The association between BRCA1-IRIS overexpression and overexpression/activation of AKT and survivin in breast tumors.
Staining
Score AKT1 (a p=0.012) AKT2 (p=0.006) p-AKT (p=0.030) Survivin (p=0.54) Total (%)
0–1 (%) 2 (%) 3 (%) 0–1 (%) 2 (%) 3 (%) 0–1 (%) 2 (%) 3 (%) 0–1 (%) 2 (%) 3 (%)
0–1 (%) 27 (55) 20 (41) 2 (4) 19 (39) 21 (43) 9 (18) 20 (40) 16 (33) 13 (27) 24 (48) 13 (27) 12 (25) 49 (15)
IRIS 2 (%) 37 (64) 19 (33) 2 (3) 25 (43) 13 (22) 20 (35) 27 (46) 9 (16) 22 (38) 20 (34) 23 (40) 15 (26) 58 (18)
3( % ) 104 (48) 112 (57) 1 (0) 61 (28) 65 (30) 91 (42) 65 (30) 59 (27) 93 (43) 86 (40) 69 (31) 62 (29) 217 (67)
Total (%) 168 (52) 151 (47) 5 (1) 105 (32) 99 (31) 120 (37) 112 (34) 84 (26) 128 (40) 130 (40) 105 (31) 89 (27) 324 (100)
a is Fisher’s exact p-value.
doi:10.1371/journal.pone.0034102.t001
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+ and TN/BL tumors
All HER2
+/BRCA1-IRIS-negative tumors (n=6) were grade 2
(p=0.0426, Table 2). One half (n=3) of the HER2
+/BRCA1-
IRIS-negative tumors was localized tumors, while the other half
(n=3, p=0.617) was lymph node positive tumors (Table 2). In
contrast, 12 (46%) HER2
+/BRCA1-IRIS-positive tumors were
grade 2 and 14 (53%) were grade 3 tumors (p=0.0221, Table 2).
Eleven (44%) HER2
+/BRCA1-IRIS-positive tumors were local-
ized tumors, 8 (31%) were lymph-node positive tumors, and 7
(25%) showed distant metastases (p=0.0201, Table 2). Further, all
TN/BL/BRCA1-IRIS-negative tumors (n=9) were grade 2
tumors (p=0.667, Table 2). Six (67%) of the TN/BL/BRCA1-
IRIS-negative tumors were localized tumors and 3 (33%) were
lymph-node positive tumors (p=0.0421, Table 2). In contrast, 25
(40%) TN/BL/BRCA1-IRIS-poitive tumors were grade 2 tumors;
38 (60%) were grade 3 tumors (p=0.0152). Thirty-five TN/BL/
BRCA1-IRIS-positive tumors (56%) were localized tumors; 20
(32%) were lymph-node positive tumors; and 5 (8%) showed
distant metastasis (p=0.0184, Table 2).
Finally, BRCA1-IRIS positivity significantly reduced age at
diagnosis in HER2
+ (51.4616.2 vs. 64.5613.2, p#0.05,n = 1 4 )
and TN/BL (48.9610.1 vs. 70.866.8, p#0.01,n = 2 3 )t u m o r s .
Surprisingly, however, TN/BL/BRCA1-IRIS-positive tumor size
was significantly larger than that of HER2
+/BRCA1-IRIS-positive
tumors (30.6619.3 vs.16.169.7, p#0.05). Taken together, these data
show that the increase in BRCA1-IRIS expression correlates with
enhanced aggressive breast tumor behavior and adverse outcomes,
especially in patients with HER2
+ or TN/BL breast tumor subtypes.
BRCA1-IRIS overexpressing HME cells form subcuta-
neous tumors in SCID mice To directly assess BRCA1-IRIS
tumor inducing potential, a xenograft mouse model was
developed. TERT-immortalized HME cells (hereafter HME/
TERT) overexpressing LT, BRCA1-IRIS, Ras
V12 (negative
controls, see [26]), LT and Ras
V12 (positive control, see [26]) or
LT and BRCA1-IRIS were subcutaneously injected in 6 to 8
week-old female SCID mice (n=10/cell line). All cell lines
expressed luciferase to be visualized in living animals and tumor
formation was analyzed by Xenogen in vivo imaging weekly or by
caliper measurement every 3
rd day. According to published data,
high-level Ras
V12 is required to induce tumor formation using
immortalized HME cells [26]. Indeed, the HME cells we used
expressed equally high levels of LT, Ras
V12 and BRCA1-IRIS
(Figure S2A).
As expected, immortalized HME cells overexpressing 1
oncogene (LT, Ras
V12 or BRCA1-IRIS) failed to form tumors
(Figure 4A and Figure S2B), whereas 8 of 10 mice injected with
immortalized HME cells expressing LT/Ras
V12 developed tumors
(see blue line in Figure 4A and Figure S2B). More importantly, 9
of 10 mice injected with immortalized HME cells expressing LT/
BRCA1-IRIS also developed tumors (see red line in Figure 4A and
Figure S2B). BRCA1-IRIS-induced tumors were observed earlier
than Ras
V12-induced tumors (45 vs. 53 days), although the
difference was not significant (p=0.09, compare red to blue line in
Figure 4A). Both tumors took ,12 weeks to reach ,1.5 cm
3 (the
allowable size, see blue and red lines in Figure 4A).
Histological differences between BRCA1-IRIS- and Ras
V12-
induced tumors
BRCA1-IRIS- and Ras
V12-induced subcutaneous tumors were
embedded in paraffin, sectioned at 4 mm in the middle of each
Figure 3. Correlations between BRCA1-IRIS expression and AKT1, AKT2, p-AKT and survivin in breast tumor samples. Nonparametric
Spearman rank correlation test comparing BRCA-IRIS and AKT1, AKT2, p-AKT, and survivin on 326 breast tumors TMAs. The staining for each marker
was scored as described in the text and the results were blotted. Insets show Spearman correlation coefficient (r) and p-value for each correlation.
doi:10.1371/journal.pone.0034102.g003
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analyzed by 2 pathologists. BRCA1-IRIS-, as well as Ras
V12-
induced tumors were poorly differentiated carcinomas with
histological features of high-grade epithelial malignancies, con-
tained areas with glandular differentiation (Figure 4B–E) and
showed areas with conspicuous squamous cell differentiation with
prominent keratinization (data not shown). Although a spindle cell
component (occasionally observed in human high-grade breast
cancers) was occasionally observed in both tumors, this component
was more prominent in BRCA1-IRIS-induced tumors (see arrow
in Figure 4G). In contrast, Ras
V12- and not BRCA1-IRIS-induced
tumors showed areas with ductal-like structures (see arrows in
Figure 4F). These data suggest that BRCA1-IRIS overexpression
promotes formation of more aggressive tumors.
In keeping with that Ras
V12-induced tumors were well
circumscribed (see arrows in Figure 4B and 4D), whereas
BRCA1-IRIS-induced tumors showed destructive growth patterns
(see arrow in Figure 4C and 4E) manifested by invasion of the
adjacent native mouse parenchyma and surrounding tissues, such
as bone (not shown) and neural tissues (see arrowheads in
Figure 4E). Finally, although BRCA1-IRIS-induced tumors were
slightly larger in size than Ras
V12-induced tumors, the difference
was not significant (p=0.09, Figure 4A). It is possible that because
BRCA1-IRIS-induced tumors were highly proliferative (see higher
mitotic figures per high-power field, Table 3) and at the same time
highly necrotic than Ras
V12-induced tumors (for comparison
throughout the tumors see Figure S3), BRCA1-IRIS-induced
tumors perhaps appear smaller. These data show that BRCA1-
IRIS overexpression is oncogenic promoting subcutaneous tumor
formation in SCID mice.
Immunohistochemical differences between BRCA1-IRIS-
and Ras
V12-induced tumors
To extend these data to expression of the survival factors
AKT1, AKT2, p-AKT, and survivin, adjacent sections from each
tumor were immunohistochemically stained with BRCA1-IRIS,
AKT1, AKT2, p-AKT, survivin, and BRCA1/p220 antibodies.
Unexpectedly, we observed increase BRCA1-IRIS expression not
only as would be expected in BRCA1-IRIS-induced tumors
(Figure 5B) but also in Ras
V12-induced tumors (Figure 5A). These
data suggest that BRCA1-IRIS expression increases upon tumor
initiation. Moreover, higher AKT1, AKT2, p-AKT, and survivin
were detected in BRCA1-IRIS-induced tumors (see examples in
Figure 5D, F, H, and J) compared to Ras
V12-induced tumors (see
examples in Figure 5C, E, G, and I).
Quantitative analysis showed that AKT1, AKT2, and p-AKT
antibodies stained all the cells, while survivin antibody stained
,50% of the cells per high power field in BRCA1-IRIS induced
tumors (Table 3). In contrast, in Ras
V12-induced tumors, the
AKT1, AKT2, and p-AKT antibodies stained ,50% of the cells,
and survivin antibody stained ,25% of the cells per high power
field (Table 3). The staining intensity per cell for each of these
Table 2. Relationships between BRCA1-IRIS level and marker expression and tumor characteristics in Her2
+ and TN/BL breast
cancer tumor samples.
Her2
+ (n=32) TN/BL (n=72)
IRIS-positive IRIS-negative IRIS-positive IRIS-negative
Characteristics (%) (%) (%) (%)
(n=26) (n=6) (n=63) (n=9)
AKT-positive (3+ and 2+) 19 (73) 3 (50) 54 (86) 7 (78)
AKT-positive (1+ and 0) 7 (27) 3 (50) 9 (14) 2 (22)
ar 0.752 0.002 0.748 0.009
bp-value 0.000009 0.621 0.00043 0.492
Surv-positive (3+ and 2+) 26 (100) 5 (83) 53 (84) 7 (78)
Surv-positive (1+ and 0) 0 (0) 1 (17) 10 (16) 2 (22)
ar 0.859 0.03 0.834 0.008
bp-value 0.000001 0.822 0.0038 0.432
Tumor Grade (as modified nuclear grade)
1 0( 0 ) 0( 0 ) 0( 0 ) 0( 0 )
2 12 (46) 6 (100) 25 (40) 9 (100)
3 14 (53) 0 (0) 38 (60) 0 (0)
cp-value 0.0221 0.0426 0.0152 0.667
Tumor Stage
In situ 0( 0 ) 0( 0 ) 3( 5 ) 0( 0 )
Localized 11 (44) 3 (50) 35 (56) 6 (67)
Lymph-node 8 (31) 3 (50) 20 (32) 3 (33)
Distant Mets 7 (25) 0 (0) 5 (8) 0 (0)
cp-value 0.0201 0.617 0.0184 0.0421
aSpearman rank coefficient test correlation (r),
bSpearman rank coefficient test p-value,
cTo compare multiple groups with one control group, analysis of variance (ANOVA) was used.
p-values (two-sided) ,0.05 were considered statistically significant.
doi:10.1371/journal.pone.0034102.t002
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compared to cells from Ras
V12-induced tumors (Table 3). These
data show that, like cultured HOSE cells [23], BRCA1-IRIS
overexpression triggers the expression and activation of AKT and
survivin in HME cells, in vivo.
Interestingly, Ras
V12-induced tumors maintained high BRCA1/
p220 expression (Figure S4a, c and e and Table 3), whereas in
BRCA1-IRIS-induced tumors, the expression of BRCA1/p220
was virtually absent (Figure S4b, d and f and Table 3). Another
prominent difference is that Ras
V12-induced tumors stained
Figure 4. BRCA1-IRIS-induced tumors show more aggressive phenotypes than Ras
V12-induced tumors. (A) The volume of subcutaneous
tumor formed in SCID mice injected with immortalized HME cells expressing, LT, Ras
V12, BRCA1-IRIS alone, or LT and Ras
V12, or LT and BRCA1-IRIS.
Results are expressed as the mean of 6 tumors 6 SD at the indicated time points after injection. Histology of these subcutaneous tumors as shown
under light microscope of H&E stained sections. (B–C) Show low and high magnification images, respectively of a poorly differentiated Ras
V12-
induced tumor. (D–E) Show low and high magnification images, respectively of a poorly differentiated BRCA1-IRIS-induced tumor. Only in BRCA1-IRIS-
induced tumors, we were able to see tumors cells invading mouse muscle tissues (arrow in E) or nerves (arrowheads in E). (F) Show poorly
differentiated Ras
V12-induced tumor with large pleomorphic nuclei and prominent nucleoli as well as ductal-like structures (arrows in F). (G) Show
poorly differentiated BRCA1-IRIS-induced tumor with large pleomorphic nuclei and prominent nucleoli and a large component of spindle-like tumor
cells (see arrow in G). Bars, 800 mm in B and D, 400 mm in C, and E, 200 mm in F and G.
doi:10.1371/journal.pone.0034102.g004
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IRIS-induced tumors stained negative (compare A to B in Figure
S5). In contrast, BRCA1-IRIS-induced tumors stained positive for
the mesenchymal marker; vimentin, whereas Ras
V12-induced
tumors stained negative (compare C to D in Figure S5). These
data show that BRCA1-IRIS overexpression promotes formation
of aggressive tumors, by upregulating expression of survival
factors; such as AKT and survivin, suppressing expression of
tumor suppressors; such as BRCA1/p220, and/or by inducing
epithelial to mesenchymal transition (EMT), in vivo.
Upregulation of rat BRCA1-IRIS in primary as well as
invasive rat mammary tumors
It is difficult to study human breast cancer progression from an in
situ tumor to invasive cancer. Rats treated with N-methyl-N-
nitrosourea (NMU) develop primary in situ breast tumors that are
similartolow-gradeestrogen-receptorpositive humanbreast cancers
[32]. Serial transplantation of these primary tumors in syngeneic
hosts leads to gradual progression to a higher-grade invasive disease
[33]. Invasive tumors, as with those in humans, usually lose p63
expression and basement membrane integrity [33] and demonstrate
a more mesenchymal phenotype with increased vimentin expression
and decreased epithelial marker expression [33].
To directly assess the involvement of BRCA1-IRIS in breast
cancer progression, primary tumors from NMU-treated rats, as
well as their invasive transplants, were analyzed for the expression
of rat BRCA1-IRIS mRNA using RT/PCR (a rat BRCA1-IRIS
specific antibody is currently unavailable). The primers used for
this study detect a segment in the intron 11 of rat BRCA1-IRIS
transcript. First, we analyzed the expression of rat BRCA1-IRIS
mRNA in several rat adult tissues, including several normal
mammary glands. Rat BRCA1-IRIS mRNA is expressed at high
level in some tissues, e.g., spleen (Figure 6A), while at low to
undetectable level in others, e.g., heart and normal mammary
gland (Figure 6A). Rat BRCA1-IRIS mRNA expression varied in 8
primary tumors. Some primary tumors (e.g., P3, 5, 7 and 8,
Figure 6B) expressed high levels, whereas others (e.g., P1, 2, 4 and
6 in Figure 6B) expressed low to undetectable levels. Interestingly,
an inverse correlation with rat ERa mRNA expression in these
primary tumors was observed (Figure 6B, see also [22]). These
data suggest that rat BRCA1-IRIS mRNA increases in a subset of
primary breast tumors that express low ERa mRNA (perhaps
belonging to HER2
+ or TN/BL tumor subtypes).
Next, 3 of the low rat BRCA1-IRIS mRNA expressing primary
tumors, namely P2, 4 and 6 were transplanted for several rounds
in syngeneic hosts. The expression of rat BRCA1-IRIS and ERa
Table 3. Immunohistochemical and pathologic characteristics significantly different in LT/Ras
V12 vs. LT/IRIS subcutaneous tumors.
LT/Ras
V12 (n=8) LT/IRIS (n=9) p-value
N( % ) N( % )
BRCA1-IRIS/20 high power fields
Total 120 116
Nuclear 120 (100) 116 (100)
Intensity 0 (0) 0 (0)
BRCA1/p220/20 high power fields
Total 99 97
Nuclear 83 (84) 10 (11) #0.01
Intensity 16 (16) 87 (89) #0.01
AKT1/20 high power fields
Total 104 108
Positive 46 (44) 108 (100) #0.05
Intensity 2 (40) 5 (100) #0.01
AKT2/20 high power fields
Total 103 106
Positive 61 (58) 106 (100) #0.05
Intensity 2 (40) 5 (100) #0.01
p-AKT/20 high power fields
Total 101 102
Positive 59 (59) 102 (100) #0.05
Intensity 2 (40) 5 (100) #0.01
Survivin/20 high power fields
Total 102 107
Positive 24 (24) 57 (53) #0.05
Intensity 2 (40) 5 (100) #0.05
Mitotic figures/20 high power fields
Total 102 95
positive 4 (4) 14 (15) #0.01
doi:10.1371/journal.pone.0034102.t003
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BRCA1-IRIS mRNA rose 3–4 fold in these tumors during the 1
st
transplants (compare 2Ii to P2, 4Ii to P4 and 6Ii to P6 in Figure 6C)
and rose even further to 6–9 fold in the 4
th transplants (see 2Iiv,
4Iiv and 6Iiv in Figure 6C). Importantly, while these tumors
expressed high ERa mRNA level as primaries (see P2, 4 and 6 in
Figure 6C), in the transplants, ERa mRNA levels decreased
significantly when rat BRCA1-IRIS mRNA levels increased
(Figure 6C). These data show a gradual and continuous increase
in rat BRCA1-IRIS mRNA expression during breast cancer
progression/invasion, which correlates with significant decrease
in the expression of rat ERa mRNA and strongly support the
notion that BRCA1-IRIS overexpression is involved in breast
cancer progression, most likely of the HER2
+ and/or TN/BL
subtypes.
Discussion
Several lines of evidence presented in this study indicate that
BRCA1-IRIS may act as a breast cancer oncogene that induces
aggressive breast cancer when overexpressed. First, BRCA1-IRIS
is overexpressed in the majority of tumors analyzed, especially
from the HER2
+ and TN/BL subtypes. Second, positive
correlation between BRCA1-IRIS expression and the expression
of the tumor inducing proteins, AKT and survivin, while negative
correlation with the expression level of the tumor suppressor
BRCA1/p220, especially in HER2
+ and TN/BL tumors was
detected as well. Third, BRCA1-IRIS overexpression was
associated with poor prognosis and outcome in breast carcinoma
of the HER2
+ and TN/BL subtypes. Forth, BRCA1-IRIS
overexpression transforms HME cells in vitro [22–25] and HME
cells overexpressing BRCA1-IRIS (in combination with TERT
and LT) form tumors in vivo (this study). Finally, breast tumor
formation and progression in rats induced by the carcinogen,
NMU was associated with induction in rat BRCA1-IRIS (mRNA)
expression.
Although HME cells overexpressing TERT/LT/Ras
V12 or /
BRCA1-IRIS both developed subcutaneous tumors when injected
in SCID mice (Figure 4), and although Ras
V12-induced tumors
also showed high BRCA1-IRIS expression (compare A to B in
Figure 5 and c to d in Figure S4), only BRCA1-IRIS-induced
tumors were invasive. This may be explained by the fact that only
BRCA1-IRIS-induced tumors have lost expression of the tumor
suppressor BRCA1/p220 (compare f to e in Figure S4). It is
possible that loss of BRCA/p220 combined with BRCA1-IRIS
overexpression generates much more aggressive, invasive, and/or
metastatic tumors. Not surprisingly, there have been no Ras
activating mutations ever detected in breast cancers. Alternatively,
it is possible that the dramatic increase in AKT and survivin
expression and/or activation in BRCA1-IRIS-induced tumors and
not Ras
V12-induced tumors (see Figure 5) generate tumor cells that
are more aggressive. In fact, in cultured cells, BRCA1-IRIS, and
not Ras
V12 overexpressing cells showed high level of proliferation
and low level of apoptosis (data not shown).
What is the mechanism responsible for enhanced BRCA1-IRIS
expression in Ras
V12-induced tumors? It was recently shown that
oncogenic Ras overexpression decrease the expression of the
mRNA 39-UTR binding and destabilizing proteins, AUF1, during
mammary cell transformation [34]. Interestingly, we recently
found that the 39-UTR of BRCA1-IRIS mRNA contained binding
sites for AUF1 (submitted). It is possible that the downregulation of
these factors by Ras
V12 overexpression stabilizes BRCA1-IRIS
mRNA, leading to BRCA1-IRIS protein overexpression. Another
Figure 5. Immunohistochemical analysis of Ras
V12 or BRCA1-
IRIS-induced subcutaneous tumors. Representative high magnifi-
cation sections from tumor xenografts developed in mice injected with
HME cells expression TERT/LT/Ras
V12 (A, C, E, G and I) or TERT/LT/IRIS (B,
D, F, H and J) stained for BRCA1-IRIS (A and B), AKT1 (C and D), AKT2 (E
and F), p-AKT (G and H) and survivin (I and J). Bar is 200 mm.
doi:10.1371/journal.pone.0034102.g005
Figure 6. BRCA1-IRIS mRNA expression in NMU-induced primary and invasive breast tumors. (A) RT/PCR analysis of rat BRCA1-IRIS mRNA
expression in normal adult rat tissues (left) and several adult rat mammary glands (right). (B) RT/PCR analysis of the expression of ERa and BRCA1-IRIS
mRNAs in several primary rat breast tumors generated flowing NMU treatment (P1–P8). (C) RT/PCR analysis of the expression of ERa and BRCA1-IRIS
mRNAs in normal gland (N), three primary tumors P2, P4 and P6 and the first (2Ii, 4Ii and 6Ii) or the fourth (2Iiv, 4Iiv and 6Iiv) invasive tumors
generated following serial transplantation of the mentioned primary tumors.
doi:10.1371/journal.pone.0034102.g006
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by up- and/or down-regulating specific transcription factors. In
this regard it was shown recently that Ras
V12 overexpression
down-regulates the expression of vitamin D during mammary
epithelial cell transformation [35]. Whether this affects BRCA1-
IRIS transcription remains to be seen.
Although relatively similar size subcutaneous tumors were
induced by Ras
V12- or BRCA1-IRIS-overexpression in SCID
mice (Figure 4A), only BRCA1-IRIS-induced tumors showed
increased aggressiveness (Figure 4). It is possible that because
Ras
V12-induced tumors maintained high expression levels of the
tumor suppressor BRCA1/p220, this then contributed to the low
aggressive phenotype in these tumors as compared to BRCA1-
IRIS-induced tumors that lost BRCA1/p220 expression. Alterna-
tively, BRCA1-IRIS-idnuced tumors were more proliferative
(Table 3), as well as more necrotic (Figure 4B), than Ras
V12-
induced tumors. This might contribute to the apparent smaller size
they show.
Necrosis is a hallmark of increased hypoxia within the tumor,
due to lack of adequate vascular supply [36]. Necrosis is known to
increase chronic ischemia, leading to infarction that triggers both
microphage infiltration in tumors and angiogenesis [36]. The fact
that BRCA1-IRIS- and not Ras
V12-induced tumors showed
increased necrosis throughout the tumors (compare b, d and f to
a, c and e in Figure S3), suggests that they are hypoxic and support
the fact that they are much more invasive. It is also important to
point out that necrosis was shown recently to be a typical
representative of basal-like breast cancer [37], and that in breast
cancer patients whose tumors overexpress HER2, higher levels of
activated AKT2 and the hypoxic-induced protein; HIF-1a [38–
40] were observed. AKT2 and HIF-1a activate transcription of a
plethora of genes involved in cancer cells proliferation, survival,
and progression [39,40]. Thus, the fact that BRCA1-IRIS
expression was high in these tumors is in line with them being
aggressive (see above). Furthermore, recent evidence showed that
Twist upregulates AKT2 expression in breast cancer cells leading
to tumor development and progression [41]. Twist’s role in the
induction of the EMT is well known. In keeping with that BRCA1-
IRIS- and not Ras
V12-induced subcutaneous tumors showed
increased expression of mesenchymal proteins, but decreased
expression of epithelial proteins (see Figure S5).
In conclusion, we have delineated a novel BRCA1-IRIS-
dependent oncogenic pathway through activation of AKT and
survivin. Collectively, our data suggest that BRCA1-IRIS
overexpression is associated with tumors that are often drug
resistant ([24,25] and this study), such as HER2
+, TN/BL, and
perhaps BRCA1/p220-associated tumors. Finally, our data
provide proof of concept that chemotherapeutic targeting of
BRCA1-IRIS might decrease the drug resistance phenotype of
these tumors and their metastatic potential.
Materials and Methods
Cell culture and establishment of doxycycline-dependent
BRCA1-IRIS expressing HME cell lines
Human mammary epithelial (HME) cells were cultured in
MEGM modified minimum medium (Lonza). BRCA1-IRIS full-
length cDNA including the entire 39-UTR was amplified using
PCR from HME total RNA using primers described earlier [20]
and was cloned into the pRevTRE plasmid (Clontech). The
authenticity of the construct was verified by sequencing. HME
cells transfected with the pTet-ON vector (the inducer, Clontech)
were infected with retrovirus pRev-TRE-BRCA1-IRIS+39UTR,
selected with 150 mg/ml hygromycin B (Sigma), and clones were
identified. Doxycycline (1–2 mg, Clontech) inducible expression of
BRCA1-IRIS was monitored by real time RT/PCR and/or
Western analysis using His- and/or BRCA1-IRIS-specific anti-
body (see Figure 1E).
Antibodies
Anti-human BRCA1-IRIS antibody was raised in mice
immunized with the BRCA1-IRIS intron-11 peptide
(GIGTRFLCLPQSIYRSELNVYAFGEHILQISKYS) fused to
glutathione S-transferase (GST) synthesized in Escherichia coli and
purified on glutathione Sepharose-4B (GSSH) beads as described
earlier [20]. For immunohistochemistry staining, this antibody was
used at 1:50 dilution as a hybridoma culture medium. The
specificity of this antibody was first confirmed by depletion on a
column containing GST-intron 11 peptide, followed by Western
analysis and immunohistochemistry analysis, and in both cases no
signal was detected. Rabbit anti-AKT1 (C73H10, produced
against a synthetic peptide surrounding Leu110 of human
AKT1 protein), and -AKT2 (D6G4, produced by immunizing
animals with a synthetic peptide corresponding to residues in
human AKT2) monoclonal antibodies, were from Cell Signaling
(Beverly, MA) used at 1:400 dilutions for immunohistochemistry
staining, and did not cross-react. Rabbit anti-p-AKT antibody was
a mixture (1:1, i.e. 1:50 dilution) of anti-phospho-AKT (Ser473,
736E11, produced by immunizing animals with a synthetic
phospho-peptide corresponding to residues surrounding Ser473
of AKT1) and -phospho-AKT (Thr308, C31E5E, produced by
immunizing animals with a synthetic phospho-peptide corre-
sponding to residues around Thr308 of AKT1), and were from
Cell Signaling. Both detect endogenous levels of AKT1 only when
phosphorylated at Ser473 or Thr308, and detect AKT2 and
AKT3 only when phosphorylated at equivalent sites. Rabbit
polyclonal anti-survivin antibody (abcam, ab469) was used. Mouse
monoclonal anti-BRCA1/p220 ‘‘SG11’’ (detects an epitope in the
last 17 amino acid of BRCA1/p220) was used to detect BRCA1/
p220 and 9E10 was used to detect Myc tag.
Subcutaneous tumorigenicity assay and in vivo imaging
of subcutaneous tumors
All animal experiments were approved by the University of
Hawaii ‘‘Institutional Animal Care and Use Committee’’ (IA-
CUC). The animals used were 6 to 8-week-old immune-
compromised athymic SCID (NOD.CB17-Prkdc
scid/J, Jackson
Laboratory) female mice. The Weinberg laboratory [26] recently
showed that HME cells form xenograft or orthotopic tumors in
SCID mice only when expressing 3 oncogenes (TERT, LT and X
[variable]). Thus, to study the oncogenic effect of BRCA1-IRIS,
we subcutaneously injected 5 million HME cells expressing
TERT, TERT/LT, TERT/BRCA1-IRIS, or TERT/Ras
V12 (as
negative controls), TERT/LT/Ras
V12 (as positive control), and
compared those to cells expressing TERT/LT/BRCA1-IRIS. All
cell lines also expressed luciferase and were injected in 200 mlo f
PBS/matrigel (1:1) using a 25-gauge needle.
Tumors were monitored with the IVIS luciferase machine
(XenogenH) weekly. In brief, mice were injected intraperitoneally
using 25G needle with 100 ml of D-luciferin solution (XenogenH)
prepared at 15 mg/ml in PBS, and anesthetized using a mix of
oxygen and isoflurane gas. Tumors were visualized by a CCD
camera within 15 minutes; during which mice were maintained
asleep by placing them right (injection) side up and their noses in a
nose-cone with a flow of anesthesia gas. Pictures of the tumors are
shown in supplementary information. Tumor size was measured
every third day by caliper (Life Sciences Instruments). Tumor
initiation was defined as the time when tumors were 3 mm in
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time of cell injection. Mice were sacrificed when the tumors grew
to .1.5 cm in diameter or after 12 weeks of monitoring. Tumor
volume was calculated with the formula 4/3pr
3 (where r is the
tumor radius). Tumors were fixed in formalin immediately
following dissection and cut at 4 mm for histological and
immunohistochemical analysis.
Immunohistochemical analysis of paraffin-embedded
tumor samples
Mouse tumors were fixed in formalin immediately following
resection for 24 hours, PBS for another 24 hours (if the time fell
over the weekend); otherwise, they were directly embedded in
paraffin. For immunohistochemical staining, human or mouse
tumor sections were deparaffinized and rehydrated with deionized
water. Epitope retrieval for AKT1, AKT2, p-AKT, survivin and
BRCA1/p220 was done by heating the slides in 10 mM citrate
buffer (pH 6.0) using an electric pressure cooker, ,15 psi at 95–
120uC for 40 minutes, then rinsed in wash buffer for 5–20 minutes
prior to staining. Epitope retrieval for BRCA1-IRIS staining was
done by incubating the slides for 20 minutes at 37uC with 10 mM
pepsin. On an automated system (Dako Autostainer) slides were
exposed to 3% hydrogen peroxide for 5 minutes, followed by
incubation with 1u antibody for 30 minutes, followed by several
washes with Tris-buffered saline (TBS), and then incubation with
2u antibody for 30 minutes using the HRP polymer system. Slides
were then developed with 3,39-diaminobenzidine (DAB) for
5 minutes, counterstained with Meyer’s hematoxylin for 5 min-
utes, and cover-slipped. In some experiments, a rabbit polyclonal
BRCA1-IRIS antibody (also generated against an epitope in
intron11 part of BRCA1-IRIS) was used and gave us identical
results.
Scoring for immunohistochemical staining of the slides
Here, we used two cohorts of breast tumor samples one set was
purchased from Biomax.us, that contained 66 normal/cancer
adjacent samples, 180 DCIS, 100 invasive tumors and 165
metastatic tumor samples. The second cohort was obtained from
archived retrospectively collected tumors by the Hawaiian
Surveillance, Epidemiology and End Results (SEER) Program, that
contained in addition to 326 breast tumor samples, several disease-
free tissue samples (i.e., kidney, liver, placenta, spleen, and normal
breast) that were used as positive controls. All work with human
tumor samples was approved by the University of Hawaii IRB
committee and was performed after obtaining permission to use
the archived samples, and all data was either anonymized or made
anonymous by the researchers. As negative control, BRCA1-IRIS
and the other 1u antibodies were replaced with TBS or by
antibodies depleted prior to incubation with sections. Expression
of membranous, cytoplasmic, or nuclear staining for the different
antibodies was scored as follows; 0=negative if ,1% of the cells
stained; 1+=weak if between 1–10% of cells stained; 2+=medi-
um if between 10%–50% of cells stained; 3+=strong if .50% of
cells stained. Scores of 0 and 1+ were combined as negative
tumors. All tumors and staining were evaluated under 46and 106
magnifications, blindly, by 2 pathologists. The same criteria were
used for the mouse tumors.
Statistical analysis
Comparisons of statistical differences were done using the
Student t-test for paired and unpaired data. Statistical significance
was assumed at a p-value of #0.05. To compare multiple groups
with 1 control group, analysis of variance (ANOVA) was used. The
criterion for significance (p-value) was set as mentioned in the
figures. The correlation between the level of BRCA1-IRIS
expression and the histological grade was analyzed using the
Fisher exact test. Nonparametric correlation test (Spearman rank
correlation test) using Spearman correlation coefficient (r) was done
between expressions of BRCA1-IRIS and AKT1, AKT2, p-AKT,
and survivin.
Supporting Information
Figure S1 Expression of BRCA1-IRIS in unaffected
patient’s tissues. Tissue samples from liver (A and B), placenta
(C and D), spleen (E and F), and kidney (G and H) were all stained
with mouse anti-BRCA1-IRIS monoclonal antibody. Note lack of
BRCA1-IRIS expression in adult kidney tissue, while high
expression in adult liver, placenta, and spleen tissues.
(TIF)
Figure S2 Subcutaneous tumor formation using HME
cells expressing TERT/LT/Ras
V12 or /BRCA1-IRIS. (A)
Representative images of luciferase signals in mice injected with
HME/Luc cells expressing TERT, TERT/LT, TERT/IRIS,
TERT/LT/Ras
V12, or TERT/LT/IRIS mixed with matrigel at
day 1, week 5 or week 10 following cell injection.
(TIF)
Figure S3 Pronounced necrosis in BRCA1-IRIS-induced
and not Ras
V12-induced tumors. (A, C and E) are sections at
different levels; top (A), middle (C) and bottom (E) of a Ras
V12-
induced tumor. (B, D and F) are sections at different levels; top (B),
middle (D) and bottom (E) of BRCA1-IRIS induced tumor. Note
the pronounced necrosis at all levels in BRCA1-IRIS- (arrows in
B, D and F) and not Ras
V12-induced tumors.
(TIF)
Figure S4 Loss of BRCA1/p220 expression in BRCA1-
IRIS- and not Ras
V12-induced tumors. Representative
sections from Ras
V12- (a, c, and e) or BRCA1-IRIS- (b, d, and f)
induced tumors stained with H&E (a and b), for BRCA1-IRIS (c
and d) or BRCA1/p220 (e and f).
(TIF)
Figure S5 Loss of epithelial marker and gain of
mesenchymal marker expression only in BRCA1-IRIS-
induced tumors. Representative sections from Ras
V12- (A and
C) or BRCA1-IRIS- (B and D) induced tumors double stained for
p63 and cytokeratin (CK) 19 (A and B) or cyclin (Cyc) D1, and
vimentin (C and D).
(TIF)
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